Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 232

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 232
---
 vesting date(s), determined based on the same methodology as used
to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and
with an estimated expected life using the simplified method, and in all cases based on volatility and risk free rates determined as of
the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the
assumptions used to calculate the valuation of the awards, see Note 5 to our consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 13, 2025.

88

Narrative
Disclosure to Pay Versus Performance Table

Relationship
Between Financial Performance Measures

The
graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs,
with our cumulative TSR for the fiscal years ended December 31, 2022, 2023 and 2024.

TSR
amounts reported in the graph assume an initial fixed investment of $100. We do not pay dividends.

The
graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs,
with our net loss for the fiscal years ended December 31, 2022, 2023 and 2024.

Director
Compensation

The
following table provides certain information concerning the compensation for services rendered in all capacities by each non-employee
director serving on our Board during the year ended December 31, 2024, other than Mr. Meckler, our Chief Executive Officer who did not
receive additional compensation for their service as a director and whose compensation is set forth in the Summary Compensation Table
under the section entitled Executive Compensation above. Dr. Newman, our Chief Scientific Officer, is also an employee and executive
officer, who did not receive additional compensation for his service as a director. Dr. Newman is not one of our named executive officers
for 2024 and so he does not appear in the Summary Compensation Table. Because Dr. Newman is an employee and an executive officer, he
is not required to be included in the table below.

89

    Name 
    Fees earned ($)  
    Stock awards ($)  
    Option awards ($)(1)  
    All other compensation ($)  
    Total ($) 
  
    Roger